KURA ONCOLOGY, INC. Other Nonoperating Income (Expense)
KURA ONCOLOGY, INC. (KURA) reported Other Nonoperating Income (Expense) of $322.00 thousand for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-08-14.
Discontinued › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2015-08-14
- KURA ONCOLOGY, INC. other nonoperating income (expense) for the quarter ending 2015-06-30 was $322.00K.
- KURA ONCOLOGY, INC. other nonoperating income (expense) for the quarter ending 2015-03-31 was $212.00K.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month |
|---|---|---|
| 2015-06-30 | $322.00K 10-Q · filed 2015-08-14 | $534.00K 10-Q · filed 2015-08-14 |
| 2015-03-31 | $212.00K 10-Q · filed 2015-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |